Novel Drug Delivery Systems Fighting Glaucoma: Formulation Obstacles and Solutions

Area of Science:

• Ophthalmology
• Pharmaceutics
• Biomedical Engineering

Background:

• Glaucoma represents a significant global health challenge and a leading cause of preventable blindness.
• Early-stage glaucoma is often asymptomatic, contributing to delayed diagnosis and treatment.
• Conventional ophthalmic drug delivery methods face limitations, including poor patient adherence and suboptimal therapeutic outcomes.

Purpose of the Study:

• To provide a comprehensive overview of innovative drug delivery systems for glaucoma management.
• To explore formulation strategies for advanced ocular drug delivery technologies.
• To summarize the efficacy of novel systems in preclinical and clinical studies.

Main Methods:

• Review of scientific literature on advanced glaucoma drug delivery systems.
• Analysis of formulation approaches for in situ gels, nanosystems, ocular inserts, contact lenses, collagen corneal shields, ocular implants, microneedles, and iontophoretic devices.
• Synthesis of study results demonstrating the effectiveness of these novel systems.

Main Results:

• Various novel drug delivery systems, including in situ gels, nanosystems, and ocular implants, show promise for enhanced glaucoma treatment.
• These advanced systems aim to improve drug bioavailability, prolong ocular retention time, and increase patient compliance.
• Evidence suggests these innovative approaches can overcome limitations associated with conventional eye drops.

Conclusions:

• Novel drug delivery systems represent a significant advancement in glaucoma therapy, offering personalized and more effective treatment options.
• Continued research and development in this area are crucial for improving patient outcomes and reducing the burden of preventable blindness.
• The reviewed technologies hold the potential to revolutionize glaucoma management by enhancing therapeutic efficacy and patient adherence.